vs
Side-by-side financial comparison of Veralto (VLTO) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× Veralto). Zoetis runs the higher net margin — 25.3% vs 17.9%, a 7.4% gap on every dollar of revenue. On growth, Veralto posted the faster year-over-year revenue change (6.8% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $170.0M). Over the past eight quarters, Veralto's revenue compounded faster (6.8% CAGR vs 4.4%).
Veralto Corporation is an American technology company headquartered in Waltham, Massachusetts. It produces products related to water analytics, water treatment, marking and coding, and packaging and color.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
VLTO vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $254.0M | $603.0M |
| Gross Margin | 60.1% | 70.2% |
| Operating Margin | 23.8% | 31.9% |
| Net Margin | 17.9% | 25.3% |
| Revenue YoY | 6.8% | 3.0% |
| Net Profit YoY | 12.9% | 3.8% |
| EPS (diluted) | $1.02 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.4B |
| Q1 26 | $254.0M | — | ||
| Q4 25 | $239.0M | $603.0M | ||
| Q3 25 | $222.0M | $721.0M | ||
| Q2 25 | $225.0M | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | $227.0M | $581.0M | ||
| Q3 24 | $219.0M | $682.0M | ||
| Q2 24 | $203.0M | $624.0M |
| Q1 26 | 60.1% | — | ||
| Q4 25 | 60.1% | 70.2% | ||
| Q3 25 | 60.0% | 71.5% | ||
| Q2 25 | 60.4% | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | 59.6% | 69.5% | ||
| Q3 24 | 59.6% | 70.6% | ||
| Q2 24 | 60.1% | 71.7% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 23.2% | 31.9% | ||
| Q3 25 | 22.8% | 37.0% | ||
| Q2 25 | 24.2% | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | 22.9% | 31.6% | ||
| Q3 24 | 23.4% | 36.6% | ||
| Q2 24 | 23.2% | 33.0% |
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.0% | 25.3% | ||
| Q3 25 | 16.2% | 30.0% | ||
| Q2 25 | 16.9% | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | 16.9% | 25.1% | ||
| Q3 24 | 16.7% | 28.6% | ||
| Q2 24 | 15.8% | 26.4% |
| Q1 26 | $1.02 | — | ||
| Q4 25 | $0.95 | $1.37 | ||
| Q3 25 | $0.89 | $1.63 | ||
| Q2 25 | $0.90 | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | $0.91 | $1.29 | ||
| Q3 24 | $0.88 | $1.50 | ||
| Q2 24 | $0.81 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.3B |
| Total Assets | — | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.6B | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.8B | $3.3B | ||
| Q3 25 | $2.7B | $5.4B | ||
| Q2 25 | $2.3B | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | $2.0B | $4.8B | ||
| Q3 24 | $2.0B | $5.2B | ||
| Q2 24 | $1.7B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $7.4B | $15.5B | ||
| Q3 25 | $7.2B | $15.2B | ||
| Q2 25 | $6.6B | $14.5B | ||
| Q1 25 | — | $14.1B | ||
| Q4 24 | $6.4B | $14.2B | ||
| Q3 24 | $6.3B | $14.4B | ||
| Q2 24 | $5.9B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.94× | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.35× | — | ||
| Q2 24 | 1.57× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $182.0M | $893.0M |
| Free Cash FlowOCF − Capex | $170.0M | $732.0M |
| FCF MarginFCF / Revenue | 12.0% | 30.7% |
| Capex IntensityCapex / Revenue | 0.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $893.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $182.0M | — | ||
| Q4 25 | $270.0M | $893.0M | ||
| Q3 25 | $339.0M | $938.0M | ||
| Q2 25 | $157.0M | $486.0M | ||
| Q1 25 | — | $587.0M | ||
| Q4 24 | $285.0M | $905.0M | ||
| Q3 24 | $224.0M | $951.0M | ||
| Q2 24 | $251.0M | $502.0M |
| Q1 26 | $170.0M | — | ||
| Q4 25 | $258.0M | $732.0M | ||
| Q3 25 | $323.0M | $805.0M | ||
| Q2 25 | $142.0M | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | $263.0M | $689.0M | ||
| Q3 24 | $215.0M | $784.0M | ||
| Q2 24 | $240.0M | $370.0M |
| Q1 26 | 12.0% | — | ||
| Q4 25 | 18.4% | 30.7% | ||
| Q3 25 | 23.6% | 33.5% | ||
| Q2 25 | 10.7% | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | 19.6% | 29.7% | ||
| Q3 24 | 16.4% | 32.8% | ||
| Q2 24 | 18.6% | 15.7% |
| Q1 26 | 0.8% | — | ||
| Q4 25 | 0.9% | 6.7% | ||
| Q3 25 | 1.2% | 5.5% | ||
| Q2 25 | 1.1% | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | 1.6% | 9.3% | ||
| Q3 24 | 0.7% | 7.0% | ||
| Q2 24 | 0.9% | 5.6% |
| Q1 26 | 0.72× | — | ||
| Q4 25 | 1.13× | 1.48× | ||
| Q3 25 | 1.53× | 1.30× | ||
| Q2 25 | 0.70× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 1.26× | 1.56× | ||
| Q3 24 | 1.02× | 1.39× | ||
| Q2 24 | 1.24× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VLTO
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
